All In Biotech

Drug Trial Radar · NCT03425396

Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis

A Randomized, Double-Blinded, Adaptive Phase 2 Study to Evaluate the Safety and Efficacy of Oral Omadacycline and Oral Nitrofurantoin in the Treatment of Female Adults With Cystitis

Last checked: Nov 20, 2026Latest source record: Jun 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 225 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

225

Actual

Start

Jan 4, 2018

Primary completion

May 15, 2019

Study completion Jun 5, 2019

Sponsor

Lead sponsor
Paratek Pharmaceuticals IncIndustry
Sponsor type
Industry
First posted
Feb 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of oral omadacycline as compared to oral nitrofurantoin in the treatment of female adults with cystitis.

Conditions

  • Uncomplicated Urinary Tract Infection
  • Cystitis

Interventions

  • Omadacycline tabletsDrug

    Oral Omadacycline

  • Nitrofurantoin capsulesDrug

    Oral Nitrofurantoin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population)Time frame: Day 14 (A PTE occurred on Day 14 ± 2 days after the participant's first dose of study drug)

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Site 106

    Chula Vista, California

  • Site 101

    La Mesa, California

  • Site 109

    Los Angeles, California

  • Site 114

    Aventura, Florida

  • Site 102

    DeLand, Florida

  • Site 103

    Hialeah, Florida

  • Site 125

    Jacksonville, Florida

  • Site 121

    Miami, Florida

  • Site 130

    Miami, Florida

  • Site 115

    Miami, Florida

  • Site 127

    Miami Springs, Florida

  • Site 126

    Orlando, Florida

  • Site 113

    Newton, Kansas

  • Site 110

    Wichita, Kansas

  • Site 112

    Omaha, Nebraska

  • Site 132

    Las Vegas, Nevada

  • Site 108

    Las Vegas, Nevada

  • Site 122

    Berlin, New Jersey

  • Site 118

    Raleigh, North Carolina

  • Site 104

    Jackson, Tennessee

  • Site 105

    Smyrna, Tennessee

  • Site 131

    Houston, Texas

  • Site 120

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.